Susan Egbert

Ms. Susan Egbert


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
BTBarbara R Terlouw
Barbara R Terlouw
KBKai Blin
Kai Blin
JNJorge C Navarro-Muñoz
Jorge C Navarro-Muñoz
NANicole Avalon
Nicole Avalon
MCMarc Chevrette
Marc Chevrette
MMMarnix H. Medema
Marnix H. Medema
With an ever-increasing amount of (meta)genomic data being deposited in sequence databases, (meta)genome mining for natural product biosynthetic pathways occupies a critical role in the discovery of novel pharmaceutical drugs, crop protection agents and biomaterials. The genes that encode these pathways are often organised into biosynthetic gene clusters (BGCs). In 2015, we defined the Minimum Information about a Biosynthetic Gene cluster (MIBiG): a standardised data format that describes the minimally required information to uniquely characterise a BGC. We simultaneously constructed an accompanying online database of BGCs, which has since been widely used by the community as a reference dataset for BGCs and was expanded to 2021 entries in 2019 (MIBiG 2.0). Here, we describe MIBiG 3.0, a database update comprising large-scale validation and re-annotation of existing entries and 661 new entries. Particular attention was paid to the annotation of compound structures and biological activities, as well as protein domain selectivities. Together, these new features keep the database up-to-date, and will provide new opportunities for the scientific community to use its freely available data, e.g. for the training of new machine learning models to predict sequence-structure-function relationships for diverse natural products. MIBiG 3.0 is accessible online at https://mibig.secondarymetabolites.org/.

4 November 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
ZNZachary Nelson
Zachary Nelson
AAAbdullah Tarik Aslan
Abdullah Tarik Aslan
NBNathan P Beahm
Nathan P Beahm
MBMichelle D Blyth
Michelle D Blyth
MCMatthew Cappiello
Matthew Cappiello
ALAlfredo J. Mena Lora
Alfredo J. Mena Lora
Importance: Traditional approaches to practice guidelines frequently result in dissociation between strength of recommendation and quality of evidence. Objective: To create a clinical guideline for the diagnosis and management of urinary tract infections that addresses the gap between the evidence and recommendation strength. Evidence Review: This consensus statement and systematic review applied an approach previously established by the WikiGuidelines Group to construct collaborative clinical guidelines. In May 2023, new and existing members were solicited for questions on urinary tract infection prevention, diagnosis, and management. For each topic, literature searches were conducted up until early 2024 in any language. Evidence was reported according to the WikiGuidelines charter: clear recommendations were established only when reproducible, prospective, controlled studies provided hypothesis-confirming evidence. In the absence of such data, clinical reviews were developed discussing the available literature and associated risks and benefits of various approaches. Findings: A total of 54 members representing 12 countries reviewed 914 articles and submitted information relevant to 5 sections: prophylaxis and prevention (7 questions), diagnosis and diagnostic stewardship (7 questions), empirical treatment (3 questions), definitive treatment and antimicrobial stewardship (10 questions), and special populations and genitourinary syndromes (10 questions). Of 37 unique questions, a clear recommendation could be provided for 6 questions. In 3 of the remaining questions, a clear recommendation could only be provided for certain aspects of the question. Clinical reviews were generated for the remaining questions and aspects of questions not meeting criteria for a clear recommendation. Conclusions and Relevance: In this consensus statement that applied the WikiGuidelines method for clinical guideline development, the majority of topics relating to prevention, diagnosis, and treatment of urinary tract infections lack high-quality prospective data and clear recommendations could not be made. Randomized clinical trials are underway to address some of these gaps; however further research is of utmost importance to inform true evidence-based, rather than eminence-based practice.


2 July 2024 in Journal of Pain & Palliative Care Pharmacotherapy
Verified
Journal Article
Closed access
KIKelsey Ihns
Kelsey Ihns
KSKayleigh Starr
Kayleigh Starr
CMChloe Marchand
Chloe Marchand
JJJothsana Jaimon
Jothsana Jaimon
ASAriana Singer
Ariana Singer
SESusan Egbert
Susan Egbert
This review examines the integration of traditional pharmacological methods with alternative and complementary therapies in chronic pain management. It delves into neurostimulation techniques, highlighting their clinical outcomes and biological bases. Acupuncture's role in modulating pain pathways is explored, illustrating its balance of tradition and clinical application. The paper also covers the pain-relieving potential of herbal medicine, emphasizing natural products' significance in pain relief. Additionally, it discusses the psychological and rehabilitative dimensions of pain through psychosocial therapy and counseling. The conclusion underscores the importance of a multidisciplinary approach, integrating diverse therapies into conventional pain management to effectively treat chronic pain. This synthesis highlights the synergistic potential of combining traditional and innovative therapeutic modalities, offering a comprehensive guide for healthcare professionals in enhancing pain management practices.

4 June 2025 in Environmental Microbiology
Verified
Journal Article
Open access
SWSamantha Waterworth
Samantha Waterworth
SESusan Egbert
Susan Egbert
JSJohn Sorensen
John Sorensen
BOBarry R. O'KEefe
Barry R. O'KEefe
John BeutlerJohn Beutler
John Beutler
Lichens are pioneer species in several ecosystems, and as such are found in a variety of geographic regions and environments. Here, inspection of metagenomic data from 794 lichen samples from 34 countries reveals the presence of a complex holobiont harbouring remarkable biosynthetic capabilities, particularly in the bacterial consortia, a component that has been somewhat underappreciated. While bacteria were consistently present, their abundance varied among lichen taxa. Common bacterial genera included Microbacterium , Terribacillus , and JABEUN01 (an Acidimicrobiaceae bacterium awaiting Latin binomial naming assignment) albeit in low abundance. Lichenihabitans and Sphingomonas genera were moderately abundant, present in approximately 30% of samples, and exhibited an enrichment in the number of biosynthetic gene clusters (BGCs) predicted to encode secondary metabolites (biosynthetic potential). We found that both fungal and bacterial biosynthetic repertoires appeared to follow genus‐specific patterns but that there was greater relative homogeneity of BGCs in the fungal genera. The substantial biosynthetic diversity within lichen holobionts is evident in our findings, with the lichen‐associated bacteria emerging as a promising potential source for sustainable drug discovery.

17 December 2025 in Microbial Genomics
Verified
Journal Article
Open access
GSGarima Singh
Garima Singh
MXMaonian Xu
Maonian Xu
MZMitja Zdouc
Mitja Zdouc
APAnna Pasinato
Anna Pasinato
SESusan Egbert
Susan Egbert
MMMarnix H. Medema
Marnix H. Medema
The increasing demand for novel drug leads requires bioprospecting non-model taxa. Comparative genomics and correlative omics are a fast and efficient method for linking bioactive but genetically orphan natural products to their biosynthetic gene clusters (BGCs) and identifying potentially novel drug leads. Here we implement these approaches for the first systematic comparison of the BGC diversity in lichen-forming fungi (LFF) (comprising 20% of known fungi), prolific but underutilized producers of bioactive natural products. We first identified BGCs from all publicly available LFF genomes (111), encompassing 71 fungal genera and 23 families, and generated BGC similarity networks of each class. We recovered 5,541 BGCs grouped into 4,464 gene cluster families. We used mass spectrometry (MS) and correlative metabolomics to link five MS-identified metabolites – alectoronic acid, alpha-collatolic acid, evernic acid, stenosporic acid and perlatolic acid – to their putative BGCs. We subsequently used MS on an additional 80 species to explore the taxonomic breadth of common lichen compounds, uncovering a strong pattern between specific families and secondary metabolites. We found that (1) ~98% of the BGCs in LFF are putatively novel (uncharacterized to date), (2) lichen metabolic profiles contain a plethora of unidentified metabolites and (3) ribosomal peptide-related BGCs constitute about 20% of the LFF BGC landscape. Our study provides comprehensive insights into the BGC landscape of LFFs, highlighting unique, widespread and previously uncharacterized BGCs. We anticipate that the approach we describe will serve as a baseline for leveraging biosynthetic research in non-model organisms, inspiring further investigations into microbial dark matter.